Published on: 
Supplements and Featured Publications, The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?, Volume 12, Issue 6 Suppl

Method of Participation:

Participants must:

  • Read the learning objectives and faculty disclosures.
  • Complete and submit the post-test with a pass rate of 70% or higher.
  • Complete and submit the attendance verification form.

A statement of credit will be issued only upon receipt of completed evaluation forms, a completed post-test with a score of 70% or higher, and a completed attendance verification form. Your statement of credit will be e-mailed to you 6 to 8 weeks after receipt.


After reading "The Great Debate Part II: Should Managed Care Rely on Cost Sharing to Manage Big-ticket Biologics?" please complete the program evaluation and circle the 1 best answer to each of the following questions.

1. Any degree of copayment suppresses demand not only for inappropriate care, but also for necessary therapy.

  • False

2. There is a link between the degree of health literacy and activation a patient has and how healthy they are.

  • False

3. Some ways in which the value of a therapy can be shown to patients include:

  • Providing a clear explanation of all costs.
  • All of the above

4. Cost is usually one of the most cited reasons why patients discontinue needed therapy.

  • False

5. Remission in patients with Crohn's disease is associated with improvement in the following:

  • Patient's employment
  • All of the above

6. Increasing patient cost sharing is the most effective way to reduce healthcare costs while maintaining access to needed therapies.

  • False

7. The primary goal of patient cost sharing is:

  • Reduction of inappropriate utilization.
  • All of the above

8. Currently the fastest growing component of healthcare costs in the United States is:

  • Hospital costs.
  • Pharmaceutical costs.

9. Employers are concerned with ____ when evaluating healthcare coverage decisions for their employees.

  • Ability of a therapy to help an employee return to work (disability)
  • All of the above

10. The majority of healthcare cost increases in the United States are related to pharmaceutical products.

  • True


To enhance understanding of the challenges faced by managed care and employers when balancing access to expensive therapies with cost.


Managed care pharmacy directors, medical directors, and other managed care executives responsible for overseeing the use of biologics and managing them on behalf of health plans.


After completing this activity, participants should be able to:

  • Describe the managed care challenges associated with making biologic therapies available to the appropriate patients.
  • Understand the balance that employers maintain between healthcare costs and productivity.

Initial Live Release Date: October 7, 2005

Release Date: April 1, 2006

Expiration Date: March 31, 2007

If the participant has previously attended this program and requested or received credit, he/she may not request or receive credit for the home study version of the program.


There are no fees associated with this continuing education offering.


Genentech has provided the grant funds for this activity.

Credit Designation:

The University of Utah College of Pharmacy designates this continuing education activity for 1.5 credit hours (0.15 CEUs) of the Accreditation Council for Pharmacy Education. Universal Program Number: 068-999-05-042-H04.

The University of Utah College of Pharmacy is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. The University of Utah School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Utah School of Medicine designates this educational activity for a maximum of 1.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The University of Utah College of Pharmacy and the University of Utah School of Medicine do not recommend the use of any agent outside of the labeled indications.


Journal article learning activity.